Upgrade to SI Premium - Free Trial

BMO Capital Checking In With Novo Nordisk (NVO) Ahead of 1Q26

March 30, 2026 8:24 AM
BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $45.00 price target on Novo Nordisk (NYSE: NVO).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments